ReviewAnnals of medicine2025
Breakthroughs in diabetic retinopathy diagnosis and treatment using preclinical research models: current progress and future directions.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integrative Evidence on Sesame Supplementation for Cardiometabolic Risk Factors Relevant to Retinopathy.International journal of medical sciences · 2026Pooled it
- Glycohypoxia: a hypothesis linking chronic hyperglycemia to functional hypoxia and diabetic complications in type 2 diabetes.Medical gas research · 2026Review
- Evaluating Systemic Immune-Inflammation Index and Mortality in Diabetic Retinopathy: A NHANES 2005-2018 Cohort Study.Ophthalmology and therapy · 2026Article
- Relationship between hemoglobin levels and diabetic retinopathy in Chinese type 2 diabetes mellitus populations: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Chain mediating effect of social support and psychological resilience between quality of discharge teaching and readiness for hospital discharge in patients with diabetic retinopathy surgery.Frontiers in public health · 2026Article
- Targeting the NEK7/NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats.Endocrinology, diabetes & metabolism · 2026Article
- Development and validation of a prediction model for microvascular complications of type 2 diabetes based on inflammation-metabolism composite indicators.Frontiers in endocrinology · 2026Article
- Reassessing retinopathy risk with tirzepatide therapy.Diabetologia · 2025Article
- Insights into the pro-angiogenic effect of hydroxysafflor yellow A (HSYA): targeting HIF-1α and MMP9 in HMEC-1.Frontiers in chemistry · 2025Article
- Chitosan-basedJournal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR), a severe microvascular complication of diabetes mellitus, poses a significant global health threat with its rising prevalence amidst the diabetes pandemic. As the leading cause of vision impairment and blindness among working-age diabetic adults, DR highlights the urgent need for innovative diagnostic methods and effective therapeutic strategies. Early detection and prompt intervention are crucial for mitigating DR's devastating consequences. This narrative review explores recent advancements in basic science and translational research on DR diagnosis and treatment, leveraging cellular and animal models. It elucidates the complex pathophysiological mechanisms underlying DR, particularly hyperglycaemia-triggered oxidative stress, inflammation and aberrant angiogenesis. Streptozotocin-induced diabetic rodents and genetically engineered mice are highlighted as valuable models for understanding human DR pathogenesis and gaining mechanistic insights. The review identifies key findings from the literature, including translational gaps, emerging trends and untapped opportunities. It emphasizes the importance of interdisciplinary collaboration in advancing DR research and overcoming translational challenges. Sustained investment in preclinical research is critical for deepening our understanding of DR and refining management strategies, ultimately aiming to alleviate the global burden of vision loss attributed to this complication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.